Background and Aims Migraine is a common headache, affecting 11% of the adult population worldwide and causing significant disability. Although, there are many treatment options, these are often inadequate and with significant side effects. Transnasal sphenopalatine ganglion block (TSGB) seems to be an effective treatment for migraine, with minimal side effects. This report aims to present the results of TSGB therapy on twelve patients with chronic migraine in our Pain Department.
Methods Our team studied twelve patients, admitted to the Pain Department of GHAN, complaining about chronic migraine. After detailed history taking and based on the Simplified Diagnostic Criteria for Migraine, the diagnosis of chronic migraine was confirmed. According to patients, treatment with simple analgesics and triptans was ineffective and the decision for TSGB therapy was made. Each patient received 0.6 ml of 2% lidocaine in each nostril using the Tx360EU device. TSGB was applied every two weeks, for a total of three months.
Results Intending to evaluate the efficacy of TSGB, we assessed the recurrence rate of migraine attacks and pain intensity of each episode using the Numerical Pain Rating Scale (NPRS) on the fourth, sixth and twelfth week after the first session. Five out of twelve patients referred complete recession of migraines, while six out of twelve referred progressively significant reduction of the frequency of attacks and over 50% reduction of pain intensity in each episode. Only one patient referred no benefit from the therapy.
Conclusions TSGB is a simple, effective and painless modality for the management of chronic migraine, with minimal side effects.